ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1562

The Thromboembolism Among Hospitalized Patients with Different Types of Chronic Glomerulonephritis: A Retrospective Study Spanning 18 Years from a Single Tertiary Hospital

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Fan, Xiaohong, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
  • Ma, Jie, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
  • Li, Xuemei, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China

Chronic kidney disease is associated with hypercoagulability and platelet dysfunction. However, data on thromboembolism associating different types of chronic glomerulonephritis (CGN) are less.


We conducted a retrospective analysis using the database of hospitalization with CGN in Peking Union Medical College Hospital (PUMCH), China from 2000 through 2017. The tenth revision from the International Classification of Diseases (ICD-10) codes of discharge diagnosis was used to identify types of thromboembolism and 6 kinds of glomerulonephritis including lupus nephritis (LN), systemic vasculitis (AAV), Henoch-Schönlein purpura nephritis (HSPN), IgA nephritis (IgAN), idiopathic membrane nephropathy (IMN), minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). Cochran-Armitage trend test and Logistic regression were used for analysis.


Between 2000 and 2017, there were 15,714 hospitalizations with the aforementioned CGN. Their mean age was 51.7±19.8 years and 39.4% were males. The annual prevalence of overall thromboembolism increased steadily from 1.6% in 2000 to 6.6% in 2017 in a dose-response manner (p for trend <0.001). Among all thromboembolism cases, 49.8% had venous thromboembolism and 31.7% had a pulmonary embolism. The prevalence of thromboembolism in IgAN, FSGS, MCD, IMN, HSPN, LN, and AAV were 0.6%, 2.4%, 2.6%, 5.89%, 2.2%, 4.4%, and 5.3%, respectively. The patients with thromboembolism had a 2.30-fold increased risk of death (95%CI 1.53-3.46) after adjustment for age and gender. In multivariate analyses adjusted for multiple confounders such as gender, hypertension, diabetes, cardiovascular disease, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease, infection, LN (OR 8.15; 95% CI 5.25-12.65), IMN (OR 6.93; 95% CI 4.39-10.92), AAV (OR 4.53; 95% CI 2.66-7.72), MCD (OR 4.42; 95% CI 2.56-7.61), HSPN (OR 4.05; 95% CI 2.33-7.03), and FSGS (OR 3.18; 95% CI 1.56-6.49) were significantly associated with the increased risk of thromboembolism compared with IgAN.


In the present study, chronic glomerulonephritis, particularly lupus nephritis, idiopathic membrane nephropathy, and systemic vasculitis were independently associated with an increased risk of thromboembolism.